Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phase4 Spins Out Of Nomura To Focus On Europe

This article was originally published in Start Up

Executive Summary

When the management team at Phase4 Ventures in February 2011 spun the venture capital business out of parent Nomura, the move highlighted two important features of the VC landscape. The first is continued investor interest in Europe, which will replace the US as Phase4's primary geographic focus, and the second is the growing, and increasingly creative, role for large secondary players in the still-vulnerable VC sector.

You may also be interested in...



Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel